Showing 561 - 580 results of 1,266 for search '"Lung cancer"', query time: 0.08s Refine Results
  1. 561
  2. 562
  3. 563

    Mesenchymal Stem Cells and their Derived Exosomes Promote Malignant Phenotype of Polyploid Non-Small-Cell Lung Cancer Cells through AMPK Signaling Pathway by Lili Wang, Mingyue Ouyang, Sining Xing, Song Zhao, Shuo Liu, Lingyan Sun, Huiying Yu

    Published 2022-01-01
    “…Chemotherapy is an important method for the treatment of non-small-cell lung cancer (NSCLC), but it can lead to side effects and polyploid cancer cells. …”
    Get full text
    Article
  4. 564

    Microenvironmental β-TrCP negates amino acid transport to trigger CD8+ T cell exhaustion in human non-small cell lung cancer by Ge Li, Zhenke Wen, Sidong Xiong

    Published 2025-01-01
    “…Here, we demonstrate that reduced amino acid (aa) metabolism and mTOR inactivation are accountable for Tex in human non-small cell lung cancer (NSCLC). NSCLC cells impede the T cell-intrinsic transcription of SLC7A5 and SLC38A1, disrupting aa transport and consequently leading to mTOR inactivation. …”
    Get full text
    Article
  5. 565

    CTSG is a prognostic marker involved in immune infiltration and inhibits tumor progression though the MAPK signaling pathway in non-small cell lung cancer by Qian Dai, Xufeng Yao, Yanke Zhang, Qian Chai, Xueyi Feng, Hongbin Zhu, Lei Zhao

    Published 2024-12-01
    “…Abstract Purpose This study aims to investigate the biological roles and molecular mechanisms of Cathepsin G (CTSG) in the progression of non-small cell lung cancer (NSCLC). Methods Western blotting and immunohistochemistry analyses of clinical samples were performed to determine the expression levels of CTSG in patients with NSCLC. …”
    Get full text
    Article
  6. 566
  7. 567
  8. 568
  9. 569
  10. 570
  11. 571
  12. 572

    Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer by Jing Zhang, Wenjie Li

    Published 2025-02-01
    “…Abstract Background While clinical trials have demonstrated enduring responses to amivantamab among advanced non-small cell lung cancer (NSCLC) patients bearing EGFR exon 20 insertion mutations, the associated toxicity profile in real-world scenarios remains elusive. …”
    Get full text
    Article
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577
  18. 578
  19. 579
  20. 580